Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
By How Much Is The Focal Segmental Glomerulosclerosis Market Expected To Expand Between 2025 And 2029?
The market size for focal segmental glomerulosclerosis has demonstrated robust expansion in recent years. It is anticipated to grow from $1.46 billion in 2024 to $1.57 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.6%. The historical growth in this market can be attributed to factors such as the increasing prevalence of chronic kidney diseases, rising awareness concerning kidney disorders, the escalating incidence of end-stage renal disease, growing investment in research and development, and an expanding geriatric population.
The focal segmental glomerulosclerosis market is projected to experience substantial expansion over the coming years, set to reach $2.09 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.3%. This growth during the forecast period is attributed to an expanding volume of clinical trials, enhancements in healthcare infrastructure, a heightened need for personalized medicine, improved access to and availability of immunosuppressive medications, and an increasing call for customized therapeutic solutions. Key trends observed over the forecast duration encompass progress in genetic research, the incorporation of precision medicine, technological breakthroughs in diagnostic instruments, novel developments in immunosuppressive drug formulations, and improvements in biomarker identification.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24541&type=smp
What Are The Top Growth Drivers Impacting The Focal Segmental Glomerulosclerosis Market Outlook?
The expanding occurrence of kidney conditions is projected to stimulate the growth of the focal segmental glomerulosclerosis market in the coming period. These conditions are characterized by impaired kidney function and structure, thereby hindering their capacity to filter waste, maintain fluid equilibrium, and regulate vital bodily processes. A primary contributor to the increasing incidence of kidney diseases is diabetes, where prolonged elevated blood sugar levels inflict damage upon the kidney’s filtering units, resulting in diabetic nephropathy. Focal segmental glomerulosclerosis itself signifies the gradual scarring of these kidney filters, serving as a crucial indicator and objective for comprehending, diagnosing, and managing chronic kidney ailments. For example, in December 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated a year-on-year increase in chronic kidney disease (CKD) mortality rates for both 2021 and 2022, specifically by 4.2% and 6.2%, respectively. Consequently, the rising prevalence of kidney diseases is a significant driver for the focal segmental glomerulosclerosis market.
What Are The Primary Types Of Segments Analyzed In The Focal Segmental Glomerulosclerosis Market?
The focal segmental glomerulosclerosis market covered in this report is segmented –
1) By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis
2) By Treatment: Drug Therapy, Dialysis, Kidney Transplant, Other Treatments
3) By Drug Class: Immunosuppressants, Angiotensin Inhibitors, Corticosteroids
4) By Route Of Administration: Oral, Parenteral
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Primary Focal Segmental Glomerulosclerosis: Idiopathic Focal Segmental Glomerulosclerosis, Genetic Or Familial Focal Segmental Glomerulosclerosis, Collapsing Variant, Tip Lesion Variant, Cellular Variant, Perihilar Variant
2) By Secondary Focal Segmental Glomerulosclerosis: Virus-Associated Focal Segmental Glomerulosclerosis, Drug-Induced Focal Segmental Glomerulosclerosis, Adaptive Or Compensatory Focal Segmental Glomerulosclerosis, Other Secondary Causes
Which Key Trends Are Expected To Influence The Focal Segmental Glomerulosclerosis Market In The Coming Years?
Companies operating within the focal segmental glomerulosclerosis market are increasingly concentrating on developing innovative therapies, such as non-immunosuppressive oral medication, to enhance patient outcomes and mitigate treatment side effects. A non-immunosuppressive oral medication is an orally taken drug designed to treat diseases without weakening the immune system, thereby assisting in the management of focal segmental glomerulosclerosis by directly targeting kidney damage while avoiding immune-related complications. For example, in May 2025, Travere Therapeutics Inc., a US-based biopharmaceutical company, secured traditional approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan), specifically for the treatment of focal segmental glomerulosclerosis (FSGS). FILSPARI stands as a first-in-class therapy that operates by simultaneously blocking the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). This dual mechanism effectively reduces proteinuria in conditions such as FSGS and IgA nephropathy. Relative to existing treatments, FILSPARI delivers superior kidney protection while maintaining a favorable safety profile.
Who Are The Primary Competitors In The Global Focal Segmental Glomerulosclerosis Market?
Major companies operating in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc.
Download The Full Report For Exclusive Market Findings:
How Does The Focal Segmental Glomerulosclerosis Market Perform Across Key Geographic Regions?
North America was the largest region in the focal segmental glomerulosclerosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the focal segmental glomerulosclerosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Focal Segmental Glomerulosclerosis Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24541&type=smp
Browse Through More Reports Similar to the Global Focal Segmental Glomerulosclerosis Market 2025, By The Business Research Company
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2025
Kidney Disease Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report
Rare Kidney Diseases Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model